The CDC released updated estimates on antimicrobial-resistant pathogens, reporting that drug-resistant organisms cause 9.7 million infections and 50,800 deaths annually in the U.S. The report also identifies 19 threats spanning urgent, serious, and concerning categories. A key policy thread in the provided brief is the stated link between limited antibiotic pipeline investment and a market dysfunction that makes it hard for developers to recoup R&D costs. The brief quotes BIO and CARB-X leadership in support of market-fix proposals such as the PASTEUR Act. For biotech stakeholders, the immediate relevance is twofold: updated threat stratification can steer government and payer priorities, while legislative approaches shape what new antimicrobial economics could look like.